Publications

Hauser, RA, AJ Espay, AL Ellenbogen, HH Fernandez, SH Isaacson, PA LeWitt, WG Ondo, et al. 2023. “IPX203 versus Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson’s Disease: The RISE-PD Randomized Clinical Trial of Trial. 2023 Oct 1;80(10):1062-1069. Doi: 10.1001/Jamaneurol.2023.2679. PMID: 37578800”. JAMA Neurol.

Isaacson, SH, RA Hauser, R Pahwa, D Gray, and S Duvvuri. 2023. “Dopamine Agonists in Parkinson’s Disease: Impact of D1-Like or D2-Like Dopamine Receptor Subtype Selectivity and Avenues for Future Treatment. 2023 Jul 7;9:100212. Doi: 10.1016/J.prdoa.2023.100212. ECollection 2023. PMID: 37497384”. Clin Park Relat Disord.

Martino, D, V Karnik, R Bhidayasiri, DA Hall, RA Hauser, A Macerollo, TM Pringheim, et al. 2023. “Members of the IPMDS Rating Scales Review Committee. Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations. 2023 Jun;38(6):1008-1026. Doi: 10.1002/Mds.29392. Epub 2023 Apr 20. PMID: 37081740”. Mov Disord.

Hauser, RA, WG Ondo, L Zhang, A Bowling, B Navia, E Pappert, and SH Isaacson. 2023. “Study Investigators. Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Is the Prophylactic Use of an Antiemetic Necessary? 2023 Mar 22. Doi: 10.3233/JPD-223537. 2023;13(3):403-414. PMID: 36970914”. J Parkinsons Dis.

Hauser, RA, PA LeWitt, CH Waters, DG Grosset, and B Blank. 2023. “The Clinical Development of Levodopa Inhalation Powder. 2023 Mar-Apr 01;46(2):66-78. Doi: 10.1097/WNF.0000000000000540. Epub 2023 Jan 29. PMID: 36715241”. Clin Neuropharmacol.

Soileau, MJ, J Aldred, K Budur, N Fisseha, VS Fung, A Jeong, TE Kimber, et al. 2022. “Safety and Efficacy of Continuous Subcutaneous Foslevodopa-Foscarbidopa in Patients With Advanced Parkinson’s Disease: a Randomised, Double-Blind, Active-Controlled, Phase 3 Trial. 2022 Dec;21(12):1099-1109. Doi: 10. PMID: 36402160”. Lancet Neurol.

Camilleri, M, T Subramanian, F Pagan, S Isaacson, R Gil, RA Hauser, M Feldman, and M Goldstein. 2022. “Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease : A Randomized Controlled Trial. 2022 Dec;175(12):1666-1674. Doi: 10.7326/M22-1438. Epub 2022 Nov 8. PMID: 36343348”. Ann Intern Med.

Pahwa, R, S Fox, RA Hauser, S Isaacson, J Lytle, R Johnson, L Llorens, AE Formella, and CM Tanner. 2022. “Clinically Important Change on the Unified Dyskinesia Rating Scale Among Patients With Parkinson’s Disease Experiencing Dyskinesia. 2022 Oct 20;13:846126. Doi: 10.3389/Fneur.2022.846126. ECollection 2022. PMID: 36341088”. Front Neurol.

Pagano, G, RA Hauser, KI Taylor, J Anzures-Cabrera, M Marchesi, T Simuni, K Marek, RB Postuma, N Pavese, and . 2022. “Trial of Prasinezumab in Early-Stage Parkinson’s Disease. 2022 Aug 4;387(5):421-432. Doi: 10.1056/NEJMoa2202867. PMID: 35921451”. N Engl J Med.

Morinan, G, RA Hauser, A Schrag, J Tang, J O’Keeffe, and MDS-NMS Scale Development Study Group. 2022. “Abbreviated MDS-UPDRS for Remote Monitoring in PD Identified Using Exhaustive Computational Search. Parkinsons Dis. 2022 Jun 7;2022:2920255. Doi: 10.1155/2022/2920255. ECollection 2022. PMID: 35711334”. Parkinsons Dis.